Alkem Laboratories Ltd.

ALKEM

₹5289.85

2.07% (107.5)

Market Cap

₹63,319 Cr.

P/E

35.26

About

Alkem Laboratories Limited is a prominent global pharmaceutical company based in India. The company is known for developing, manufacturing, and marketing high-quality pharmaceutical products in variou… Read more

Alkem Laboratories Limited is a prominent global pharmaceutical company based in India. The co… Read more

Low

3447

52W Range

High

5579

Company Timeline

Subscribe now for more updates

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE

Latest

10.88%

3yr Average

17.14%

5yr Average

16.74%

Net Profit Margin

Latest

8.48%

3yr Average

13.95%

5yr Average

13.14%

ROCE

Latest

17.32%

3yr Average

23.09%

5yr Average

22.27%

Debt to Equity

Latest

0.14

3yr Average

0.22

5yr Average

0.22

Market Share

2 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

9.27 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.04 %

(as of Jul 20)

Historic

Anti-Malarial - Market Share

0.37 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.03 %

(as of May 19)

Historic

Blood Related - Market Share

0.95 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

2.02 %

(as of Nov 21)

Historic

Dermatology - Market Share

1 %

(as of Nov 21)

Historic

Endocrinology - Market Share

5.61 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

1.09 %

(as of Nov 21)

Historic

Gynecology - Market Share

3.14 %

(as of Nov 21)

Historic

Neurological - Market Share

0.01 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

3.32 %

(as of Nov 21)

Historic

Pain - Market Share

4 %

(as of Dec 22)

Historic

Pharmaceutical Sector - Market Share

0.96 %

(as of Nov 21)

Historic

Respiratory - Market Share

0.02 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.01 %

(as of May 20)

Historic

Stomatological - Market Share

0.98 %

(as of Nov 21)

Historic

Urology - Market Share

4.89 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up

Brand Wise Break-Up - India

Asset Break-Up

Operational Metrics

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Number of ANDA's Filed in Europe
Source
Number of ANDA's Approved in Europe
Source
Number of ANDA's Filed in Australia
Source
Number of ANDA's Approved by Australia
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Clavam

Taxim

Suppliers

Borosil Renewables Ltd.
Aarti Drugs Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
TCPL Packaging Ltd.
ICE Make Refrigeration Ltd.
Bliss GVS Pharma Ltd.
Empire Industries Ltd.
Zim Laboratories Ltd.

Showing 5 of 8

FAQs on Alkem Laboratories Ltd. Business

What does Alkem Laboratories do?

Alkem Laboratories Limited is a prominent Indian pharmaceutical company that develops, manufactures, and markets high-quality pharmaceutical products globally. It excels in acute and chronic therapeutic segments, supported by strong distribution networks and brand building.

Who are the competitors of Alkem Laboratories?

Alkem Laboratories major competitors are Abbott India, Glaxosmithkline Phar, Aurobindo Pharma, Lupin, Glenmark Pharma, Mankind Pharma, Gland Pharma.
Market Cap of Alkem Laboratories is ₹63,319 Crs.
While the median market cap of its peers are ₹60,854 Crs.

Is Alkem Laboratories financially stable compared to its peers?

Alkem Laboratories seems to be less financially stable compared to its peers.
Altman Z score of Alkem Laboratories is 20.04 and is ranked 4 out of its 8 competitors.

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Jun			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec